CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children
- To determine the CYP3A5 genotype in young patients with cancer who have received
- To document renal function and nephrotoxicity on one occasion between 1 month and 5
years after completion of ifosfamide treatment.
- To determine the relationship between CYP3A5 genotype and ifosfamide nephrotoxicity.
- To compare the measured glomerular filtration rate (GFR) (using a radioisotope
clearance method) with that calculated using the Cole (weight and creatinine) model.
OUTLINE: This is a multicenter study.
Nephrotoxicity assessment is performed in patients who have not undergone prior assessment*.
NOTE: *Nephrotoxicity assessment is performed once between 1 month and 5 years after
completion of ifosfamide chemotherapy.
All patients will undergo a single blood sample collection. DNA will be extracted from this
sample and genotyped for the known functional polymorphisms in CYP3A5. The technique of
restriction fragment length polymorphism (RFLP) will be used to detect any single nucleotide
polymorphisms in CYP3A5.
DNA may be obtained from stored tumor samples from patients for whom the results of renal
investigations are available, but for whom blood is not available for CYP3A5 genotyping.
University of Newcastle Upon-Tyne